Bloodless management of significantly elevated transcranial Doppler velocity value in a Jehovah's witness child with sickle cell disease: A tertiary centre experience-A case report

被引:0
作者
Nri-Ezedi, Chisom Adaobi [1 ]
Ulasi, Thomas [1 ]
Efobi, Chilota Chibuife [2 ]
Aneke, John Chinawaeze [2 ]
Ugwu, Nwanneka [1 ]
Nwosu, Chinekwu [3 ]
机构
[1] Nnamdi Azikiwe Univ, Fac Med, Dept Paediat, Nnewi Campus, Awka, Anambra State, Nigeria
[2] Nnamdi Azikiwe Univ, Fac Basic Clin Sci, Dept Haematol & Blood Transfus, Nnewi Campus, Awka, Anambra State, Nigeria
[3] Nnamdi Azikiwe Univ, Fac Med, Dept Radiol, Nnewi Campus, Awka, Anambra State, Nigeria
关键词
Sickle cell disease; transcranial Doppler velocity; Bloodless management; Hydroxyurea; Omega-3; supplementation; Jehovah's Witnesses; ACID SUPPLEMENTATION; OPEN-LABEL; ANEMIA; STROKE; TRANSFUSIONS; HYDROXYUREA; PREVENTION; OMEGA-3; FLOW;
D O I
10.1016/j.jnma.2024.01.016
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: Effective management of complications in sickle cell disease (SCD), such as stroke prevention, often necessitates the use of blood transfusions. However, individuals who adhere to the religious tenets of Jehovah's Witnesses strictly abstain from accepting blood transfusions, thereby presenting a formidable challenge in clinical decision-making. Case report: This is a case of a 3 year old child Jehovah's Witness who was found to have significantly elevated transcranial Doppler (TCD) velocity values between 193 and 203 cm/s, following routine screening. This was an otherwise clinically stable child, whose mother was diligently ensuring he had adequate medical care. Ideally, a prophylactic exchange blood transfusion program would have been commenced immediately but was not done due to due to the lack of consent from the caregiver. Patient was initially on hydroxyurea at 15 mg/kg and self medicating on omega 3 supplements and astymin syrup. Further elevation of TCD velocity upto 242 cm/s after a repeat testing, necessitated graduated increase of the dosage of hydroxyurea to 35 mg/kg to optimize its therapeutic effect, and discontinuation of omega 3 fatty acids and replacement of astymin with folic acid, vitamin C and B complex. Following these adjustments, the T CD dropped to below 190 cm/s reducing the risk of stroke in the child. Conclusion: This case report demonstrates the successful implementation of a bloodless management strategy for stroke prevention in a Jehovah's Witness child with SCD. This study contributes to the existing literature by providing valuable insights and practical guidance for healthcare providers facing similar ethical and medical dilemmas
引用
收藏
页码:247 / 251
页数:5
相关论文
共 26 条
[1]   Prevention of a first stroke by transfusions in children with sickle, cell anemia and abnormal results on transcranial Doppler ultrasonography [J].
Adams, RJ ;
McKie, VC ;
Hsu, L ;
Files, B ;
Vichinsky, E ;
Pegelow, C ;
Abboud, M ;
Gallagher, D ;
Kutlar, A ;
Nichols, FT ;
Bonds, DR ;
Brambilla, D ;
Woods, G ;
Olivieri, N ;
Driscoll, C ;
Miller, S ;
Wang, W ;
Hurlett, A ;
Scher, C ;
Berman, B ;
Carl, E ;
Jones, AM ;
Roach, ES ;
Wright, E ;
Zimmerman, RA ;
Waclawiw, M ;
Pearson, H ;
Powars, D ;
Younkin, D ;
El-Gammal, T ;
Seibert, J ;
Moye, L ;
Espeland, M ;
Murray, R ;
McKinley, R ;
McKinley, S ;
Hagner, S ;
Weiner, S ;
Estow, S ;
Yelle, M ;
Brock, K ;
Carter, E ;
Chiarucci, K ;
Debarr, M ;
Feron, P ;
Harris, S ;
Hoey, L ;
Jacques, K ;
Kuisel, L ;
Lewis, N .
NEW ENGLAND JOURNAL OF MEDICINE, 1998, 339 (01) :5-11
[2]   Hydroxyurea with dose escalation for primary stroke risk reduction in children with sickle cell anaemia in Tanzania (SPHERE): an open-label, phase 2 trial [J].
Ambrose, Emmanuela E. ;
Latham, Teresa S. ;
Songoro, Primrose ;
Charles, Mwesige ;
Lane, Adam C. ;
Stuber, Susan E. ;
Makubi, Abel N. ;
Ware, Russell E. ;
Smart, Luke R. .
LANCET HAEMATOLOGY, 2023, 10 (04) :E261-E271
[3]  
[Anonymous], 2021, Transcranial Doppler sonography (ultrasound)
[4]  
Chaturvedi P, 2023, YALE J BIOL MED, V96, P13, DOI 10.59249/ATVG1290
[5]   Transfusion support and alternatives for Jehovah's Witness patients [J].
Crowe, Elizabeth P. ;
DeSimone, Robert A. .
CURRENT OPINION IN HEMATOLOGY, 2019, 26 (06) :473-479
[6]   Omega-3 fatty acids are a potential therapy for patients with sickle cell disease [J].
Daak, Ahmed ;
Rabinowicz, Adrian ;
Ghebremeskel, Kebreab .
NATURE REVIEWS DISEASE PRIMERS, 2018, 4
[7]   Effect of omega-3 (n-3) fatty acid supplementation in patients with sickle cell anemia: randomized, double-blind, placebo-controlled trial [J].
Daak, Ahmed A. ;
Ghebremeskel, Kebreab ;
Hassan, Zahir ;
Attallah, Bakhita ;
Azan, Haj H. ;
Elbashir, Mustafa I. ;
Crawford, Michael .
AMERICAN JOURNAL OF CLINICAL NUTRITION, 2013, 97 (01) :37-44
[8]  
Egini O, 2017, BLOOD, V130
[9]   Comparative effects of DHA and EPA on cell function [J].
Gorjao, Renata ;
Azevedo-Martins, Anna Karenina ;
Rodrigues, Hosana Gomes ;
Abdulkader, Fernando ;
Arcisio-Miranda, Manoel ;
Procopio, Joaquim ;
Curi, Rui .
PHARMACOLOGY & THERAPEUTICS, 2009, 122 (01) :56-64
[10]   Large-Vessel Vasculopathy in Children With Siclde Cell Disease: A Magnetic Resonance Imaging Study of Infarct Topography and Focal Atrophy [J].
Guilliams, Kristin P. ;
Fields, Melanie E. ;
Ragan, Dustin K. ;
Chen, Yasheng ;
Eldeniz, Cihat ;
Hulbert, Monica L. ;
Binldey, Michael M. ;
Rhodes, James N. ;
Shimony, Joshua S. ;
McKinstry, Robert C. ;
Vo, Katie D. ;
An, Hongyu ;
Lee, Jin-Moo ;
Ford, Andria L. .
PEDIATRIC NEUROLOGY, 2017, 69 :49-57